To prepare oral controlled-release cilostazol formulations and evaluate their pharmacokinetics and pharmacodynamics in dogs and humans compared with a commercial twice-daily immediate-release formulation ( Pletal ) , thereby showing the potential for the development of an improved once-daily cilostazol formulation .